Could antibody infusions replace daily HIV pills?
NCT ID NCT03526848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether two lab-made antibodies (3BNC117 and 10-1074) could help people with HIV control the virus after stopping their daily antiretroviral therapy (ART). Twenty-six participants on stable ART received seven infusions of the antibodies, then paused their regular HIV medications. Researchers monitored how long it took for the virus to come back and checked for side effects. The goal was to see if these antibodies could keep the virus in check without daily pills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
3BNC117 and 10-1074 (monoclonal antibodies)
What this could lead to
If successful, this could point toward a way for people with HIV to control the virus without needing daily antiretroviral therapy.
What could go wrong
This is a very early, small phase 1 trial with only 26 participants. The antibodies may not prevent viral rebound, and the effects may not last. There is also a risk of infusion reactions or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ragon Institute of MGH, MIT, and Harvard
Boston, Massachusetts, 02114, United States
-
The Rockefeller University
New York, New York, 10065, United States